India approves second test of Biotech nasal vaccine

BBV154 The country's first nasal vaccine

The first stage test was performed on people aged 18 to 20 years

New Delhi: The first nasal vaccine against corona, developed by Bharat Biotech, has been approved for second phase testing, the Department of Biotechnology said in a statement. The first stage test was performed on people aged 18 to 60 years.

DBT said in a statement that testing of the second phase of the nasal vaccine given by Bharat Biotech has been approved. The second and third phases of the nasal vaccine have been approved, according to an earlier statement. This is the first time such a vaccine has been tested in India.

The company said in a statement that the first phase of testing had been successful and that no side effects had been reported in any of the participants. Mission Covid Security Mission was launched under the third self-contained package. According to officials, Bharat Biotech's BBV154 vaccine is the country's first nasal vaccine.